Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
BRKR 
Bruker Corporation (BRKR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: BRKR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $48.83
1 Year Target Price $48.83
| 5 | Strong Buy |
| 2 | Buy |
| 7 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 34.24% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.99B USD | Price to earnings Ratio - | 1Y Target Price 48.83 |
Price to earnings Ratio - | 1Y Target Price 48.83 | ||
Volume (30-day avg) 14 | Beta 1.17 | 52 Weeks Range 28.46 - 64.32 | Updated Date 12/8/2025 |
52 Weeks Range 28.46 - 64.32 | Updated Date 12/8/2025 | ||
Dividends yield (FY) 0.42% | Basic EPS (TTM) -0.16 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -0.61% | Operating Margin (TTM) 12.96% |
Management Effectiveness
Return on Assets (TTM) 3.68% | Return on Equity (TTM) -1.09% |
Valuation
Trailing PE - | Forward PE 20.75 | Enterprise Value 8704692624 | Price to Sales(TTM) 2.03 |
Enterprise Value 8704692624 | Price to Sales(TTM) 2.03 | ||
Enterprise Value to Revenue 2.53 | Enterprise Value to EBITDA 30.05 | Shares Outstanding 151941144 | Shares Floating 102871752 |
Shares Outstanding 151941144 | Shares Floating 102871752 | ||
Percent Insiders 31.94 | Percent Institutions 90.34 |
Upturn AI SWOT
Bruker Corporation
Company Overview
History and Background
Bruker Corporation was founded in 1999 through the merger of Bruker Instruments and Kontron Instruments. It has a history rooted in the scientific instrument industry, with predecessor companies dating back to the 1960s. The company has grown through organic development and strategic acquisitions, expanding its technological capabilities and market reach in life science research, applied markets, and diagnostics.
Core Business Areas
- Life Science Solutions: Bruker's Life Science Solutions segment offers a comprehensive portfolio of high-performance scientific instruments and analytical and diagnostic solutions. This includes mass spectrometry, nuclear magnetic resonance (NMR) spectroscopy, X-ray diffraction (XRD) and X-ray fluorescence (XRF) spectroscopy, and infrared (IR) and Raman spectroscopy. These instruments are used in research and development, drug discovery, proteomics, metabolomics, and food and beverage analysis.
- Advanced Technologies: This segment focuses on high-performance instruments for a variety of advanced applications, including materials science, semiconductor metrology, industrial process control, and scientific research. Key technologies include magnetic resonance and micro-imaging, superconducting magnets, and high-power generators and amplifiers.
- Clinical Research & Diagnostics: Bruker provides instruments and solutions for clinical research and diagnostics, with a focus on areas like microbiology, infectious disease diagnostics, and molecular diagnostics. This segment aims to accelerate diagnostic workflows and improve patient outcomes.
Leadership and Structure
Bruker Corporation is led by a seasoned executive team, with Frank H. Laukien serving as President and Chief Executive Officer. The company operates through its various divisions and business units, each focused on specific product lines and market segments. The organizational structure is designed to foster innovation and drive growth across its diverse scientific instrumentation offerings.
Top Products and Market Share
Key Offerings
- Description: Bruker's mass spectrometry platforms are leading tools for quantitative and qualitative analysis in proteomics, metabolomics, drug discovery, and clinical research. Competitors include Thermo Fisher Scientific (TSLF), Agilent Technologies (A), and SCIEX.
- Market Share Data: Bruker holds a significant share in the mass spectrometry market, particularly in specialized areas like high-resolution MS and proteomics.
- Product Name 1: Mass Spectrometry Systems (e.g., timsTOF series, MALDI-TOF MS)
- Description: Bruker is a dominant player in the NMR spectroscopy market, providing instruments essential for structural elucidation of molecules in chemistry, biology, and materials science. Competitors include JEOL Ltd. and Spinlock (which is a part of a larger conglomerate).
- Market Share Data: Bruker is a market leader in high-field NMR systems.
- Product Name 2: Nuclear Magnetic Resonance (NMR) Spectrometers
- Description: These systems are used for elemental analysis and structural determination in materials science, quality control, and mining. Key competitors include PANalytical (now Malvern Panalytical), Thermo Fisher Scientific, and Rigaku.
- Market Share Data: Bruker has a strong presence in both XRD and XRF markets.
- Product Name 3: X-ray Diffraction (XRD) and X-ray Fluorescence (XRF) Systems
- Description: The MALDI Biotyper is a rapid and accurate system for microbial identification, widely used in clinical laboratories, food safety, and environmental testing. Competitors include bioMu00e9rieux, VITEK, and other molecular diagnostics companies.
- Market Share Data: Bruker is a leader in mass spectrometry-based microbial identification.
- Product Name 4: Microbiology and Diagnostics Solutions (e.g., MALDI Biotyper)
Market Dynamics
Industry Overview
Bruker operates in the scientific instrumentation market, which is characterized by continuous innovation, demand for higher sensitivity and resolution, and increasing adoption in emerging markets. Key drivers include advancements in life sciences research (genomics, proteomics, drug discovery), the need for stringent quality control in pharmaceuticals and food safety, and the growing importance of materials science and nanotechnology.
Positioning
Bruker is a leading global manufacturer of scientific instruments, renowned for its high-performance, cutting-edge technologies. Its competitive advantages lie in its strong R&D capabilities, broad product portfolio, established customer relationships, and a focus on niche, high-value applications. The company benefits from its expertise in complex analytical techniques.
Total Addressable Market (TAM)
The global scientific instrument market is substantial and growing, with estimates varying by segment but generally projected to be tens of billions of dollars annually. Bruker is well-positioned to capture a significant portion of this TAM through its diverse offerings and focus on high-growth areas such as life sciences, diagnostics, and advanced materials. The company's strategy of offering integrated solutions and advanced technological platforms allows it to target specific high-value segments within the broader market.
Upturn SWOT Analysis
Strengths
- Strong brand reputation for high-performance scientific instruments.
- Leading technological innovation and R&D capabilities.
- Diverse product portfolio serving multiple high-growth markets.
- Established global sales and service network.
- Experienced management team with deep industry knowledge.
Weaknesses
- Relatively high cost of some advanced instrumentation, potentially limiting adoption for smaller organizations.
- Dependence on capital expenditure by research institutions and corporations.
- Potential for long sales cycles for complex systems.
- Competitive pressure from larger, more diversified companies.
Opportunities
- Growth in personalized medicine and biopharmaceutical research.
- Increasing demand for advanced materials characterization.
- Expansion in emerging markets with growing R&D investments.
- Leveraging AI and machine learning for data analysis and instrument automation.
- Strategic acquisitions to expand technological capabilities or market reach.
Threats
- Global economic downturns affecting R&D spending.
- Intensifying competition and pricing pressures.
- Rapid technological obsolescence requiring continuous innovation.
- Supply chain disruptions and raw material cost fluctuations.
- Regulatory changes impacting specific application areas.
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Agilent Technologies (A)
- Danaher Corporation (DHR)
- PerkinElmer (now Revvity) (RVTY)
- Shimadzu Corporation (non-US listed, but a key competitor)
Competitive Landscape
Bruker differentiates itself through its specialized, high-performance instrument offerings and deep scientific expertise. While larger competitors like Thermo Fisher Scientific have broader portfolios, Bruker excels in specific niches like high-field NMR and advanced mass spectrometry, often commanding premium pricing for its cutting-edge technology. The company's agility in focusing on specific technological advancements is a key advantage.
Major Acquisitions
Phenomenetics
- Year: 2023
- Acquisition Price (USD millions):
- Strategic Rationale: Acquired for its expertise in single-molecule detection technologies, likely to enhance Bruker's capabilities in areas like advanced diagnostics and life science research.
SqM
- Year: 2023
- Acquisition Price (USD millions):
- Strategic Rationale: Acquired to strengthen Bruker's capabilities in spectroscopy and related technologies, likely for integration into existing product lines or development of new solutions.
NAnalysis
- Year: 2021
- Acquisition Price (USD millions): 200
- Strategic Rationale: Acquired to expand Bruker's portfolio in portable and high-performance NMR spectroscopy, targeting new applications and markets.
Growth Trajectory and Initiatives
Historical Growth: Bruker has experienced consistent historical growth, characterized by both organic expansion and strategic acquisitions. The company has successfully integrated new technologies and expanded its market penetration across various scientific disciplines and geographic regions.
Future Projections: Analyst consensus generally forecasts continued revenue and earnings growth for Bruker Corporation, driven by innovation in key areas like life sciences, diagnostics, and materials science. The company is expected to benefit from ongoing trends in scientific research, healthcare advancements, and industrial applications requiring sophisticated analytical tools.
Recent Initiatives: Expansion of its timsTOF mass spectrometry platform for enhanced proteomics research.,Development of new diagnostic solutions to address emerging infectious diseases.,Investments in artificial intelligence and machine learning to enhance instrument performance and data analysis.,Strategic partnerships and collaborations to accelerate product development and market access.
Summary
Bruker Corporation is a strong player in the scientific instrumentation market, known for its high-performance products and technological innovation. The company exhibits consistent financial growth, robust profit margins, and a clear strategy for future expansion, particularly in life sciences and diagnostics. Key strengths lie in its R&D and specialized product offerings, though it faces intense competition and the need for continuous innovation to maintain its market position.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Bruker Corporation Investor Relations
- Company Annual Reports (10-K filings)
- Financial data aggregators (e.g., Yahoo Finance, Refinitiv)
- Industry research reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial advice. Market share data is an estimate and can vary depending on the specific market segment and data source. Financial figures and projections are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bruker Corporation
Exchange NASDAQ | Headquaters Billerica, MA, United States | ||
IPO Launch date 2000-08-04 | Chairman, CEO & President Dr. Frank H. Laukien Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 11396 | Website https://www.bruker.com |
Full time employees 11396 | Website https://www.bruker.com | ||
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.